Avalo Therapeutics, Inc. · NASDAQ:AVTX
Doyle Mittie sold 679 Avalo Therapeutics, Inc. shares (Form 4)
Traded Apr 1, 2026 · Filed Apr 3, 2026
On Apr 1, 2026, Doyle Mittie (Chief Medical Officer) sold 679 Avalo Therapeutics, Inc. shares at US$16.00 for US$10,864 under a trading plan, leaving 3,622 shares. Filed Apr 3, 2026 (Form 4).
- Sold
- 679 shares
- Price
- US$16.00
- Value
- US$10,864
- Holding after
- 3,622 shares
- Trading plan
- Yes (Made under a plan set in advance)
- Role
- Chief Medical Officer
The filing in full
| Date | Security | Transaction | Shares | Price | Holding after | Ownership |
|---|---|---|---|---|---|---|
| Apr 1, 2026 | Common Stock | Option exercise | 679 | US$8.04 | 4,301 | Direct |
| Apr 1, 2026 | Common Stock | Sale | 679 | US$16.00 | 3,622 | Direct |
Source
Related
- Avalo Therapeutics, Inc.
- Doyle Mittie
- Avalo Therapeutics, Inc. shareholders
- Form 4 · Doyle Mittie · Sep 1, 2026
- Form 4 · Doyle Mittie · Aug 19, 2026
- Form 4 · Doyle Mittie · Aug 12, 2026
- Form 4 · Doyle Mittie · Jul 29, 2026
- Form 4 · Doyle Mittie · Jul 2, 2026
- Form 4 · Sullivan Christopher Ryan · Sep 18, 2026
- Form 4 · Sullivan Christopher Ryan · Sep 11, 2026
- Form 4 · Sullivan Christopher Ryan · Aug 19, 2026
- Schedule 13G/A · Bvf Partners L P · Aug 14, 2026
- Schedule 13G/A · Nantahala Capital Management, LLC · Aug 14, 2026